title: p53 and bcl-2 immunohistochemistry in pretreatment prostate needle biopsies to predict recurrence of prostate cancer after radical prostatectomy.
abstract: OBJECTIVE
  Immunohistochemical staining of radical prostatectomy specimens for p53 and bcl-2 proteins has been shown to correlate with prostate specific antigen (PSA) recurrence in a series of patients at our institution. We analyzed the relationship between staining of diagnostic prostate needle biopsies for p53 and bcl-2, and PSA recurrence.
  
  
  METHODS
  From 1986 to 1993, 335 radical prostatectomies were performed at our hospital. Of the prostatectomy specimens 199 had been evaluated for p53 and bcl-2 proteins in a prior series. Of 139 patients with biopsy material available for analysis 129 had enough for evaluation of 1 or both markers. Prospectively obtained clinical followup data were available, with a mean followup of 6 years. Commercially available antibodies were used for immunohistochemical staining.
  
  
  RESULTS
  The overall PSA recurrence rate was 37.6% for 199 radical prostatectomy cases and 37.9% for 129 with biopsy immunohistochemical staining. Staining of prostatectomies correlated well with PSA recurrence for p53 (p = 0.004) and bcl-2 (p = 0.001). However, biopsy staining did not correlate with prostatectomy staining or PSA recurrence for either marker.
  
  
  CONCLUSIONS
  The p53 and bcl-2 biomarkers appear to be important to predict recurrence of prostate cancer when prostatectomy specimens are analyzed but this usefulness is not apparent with immunohistochemical staining of prostate biopsies. This difference may reflect sampling error and/or the heterogeneous nature of prostate cancers, and deserves further study.
authors.affiliation: Department of Surgery, Walter Reed Army Medical Center, Washington, DC, USA.
authors.forename: G B
authors.initials: GB
authors.lastname: Stackhouse
authors.forename: I A
authors.initials: IA
authors.lastname: Sesterhenn
authors.forename: J J
authors.initials: JJ
authors.lastname: Bauer
authors.forename: F K
authors.initials: FK
authors.lastname: Mostofi
authors.forename: R R
authors.initials: RR
authors.lastname: Connelly
authors.forename: S K
authors.initials: SK
authors.lastname: Srivastava
authors.forename: J W
authors.initials: JW
authors.lastname: Moul
mesh_terms: D000368:Aged; D001707:Biopsy, Needle; D005500:Follow-Up Studies; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000453:epidemiology*; D011237:Predictive Value of Tests; D011379:Prognosis; D011446:Prospective Studies; D017430:Prostate-Specific Antigen / Q000097:blood; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000097:blood / Q000737:chemistry* / Q000276:immunology / Q000473:pathology* / Q000601:surgery; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000032:analysis*; D016159:Tumor Suppressor Protein p53 / Q000032:analysis*
chemical_list: D019253:Proto-Oncogene Proteins c-bcl-2; D016159:Tumor Suppressor Protein p53; D017430:Prostate-Specific Antigen